Adjuvant Endocrine Treatment of Early Breast Cancer-Reference-Cited by-同舟云学术

Adjuvant Endocrine Treatment of Early Breast Cancer

Published:2007-04 Issue:2 Volume:21 Page:223-238
ISSN:0889-8588
Container-title:Hematology/Oncology Clinics of North America
language:en
Short-container-title:Hematology/Oncology Clinics of North America

Author:

Lønning Per Eystein

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference78 articles.

1. Ovarian ablation in early breast cancer: overview of the randomised trials;Clarke;Lancet,1996

2. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications;DelMastro;Breast Cancer Res Treat,1997

3. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study–NCICCTG MA.5;Parulekar;J Clin Oncol,2005

4. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup Trial 0100 (SWOG-8814);Albain;Proceeding of the American Society of Clinical Oncology,2002

5. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-06-13

2. Tamoxifen resistance induction results in mitoxantrone resistance in MCF-7 breast cancer cells via upregulation of ABCG2 expression;2023-03-02

3. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells;Molecular and Cellular Endocrinology;2020-04

4. Although c‑MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER‑positive breast cancer;International Journal of Oncology;2020-02-14

5. ObRb downregulation increases breast cancer cell sensitivity to tamoxifen;Tumor Biology;2015-04-07